These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 2537614

  • 1. Posttransfusion cytomegalovirus infections.
    Tegtmeier GE.
    Arch Pathol Lab Med; 1989 Mar; 113(3):236-45. PubMed ID: 2537614
    [Abstract] [Full Text] [Related]

  • 2. Cytomegalovirus infection.
    Climent C, Vélez R, Capriles JA.
    Bol Asoc Med P R; 1992 Jan; 84(1):31-3. PubMed ID: 1323967
    [Abstract] [Full Text] [Related]

  • 3. Transfusion-transmitted cytomegalovirus infection.
    Bowden RA.
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):155-66. PubMed ID: 7737939
    [Abstract] [Full Text] [Related]

  • 4. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B.
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [Abstract] [Full Text] [Related]

  • 5. Neonatal cytomegalovirus infections due to blood.
    Adler SP.
    Crit Rev Clin Lab Sci; 1986 Sep; 23(1):1-14. PubMed ID: 3004810
    [Abstract] [Full Text] [Related]

  • 6. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman A.
    Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
    [Abstract] [Full Text] [Related]

  • 7. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ, Ho WG, Bartoni K, Champlin RE.
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [Abstract] [Full Text] [Related]

  • 8. CMV and blood transfusions.
    Roback JD.
    Rev Med Virol; 2002 Sep; 12(4):211-9. PubMed ID: 12125013
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A, Bordigoni P, Witz F, Bene MC, Schmitt C, Lacour B, Sommelet D.
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
    Verdonck LF, de Graan-Hentzen YC, Dekker AW, Mudde GC, de Gast GC.
    Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus infection in seronegative patients treated with prophylaxis: case-controlled study.
    Moreno de la Higuera Díaz MA, Calvo Romero N, Sánchez-Fructuoso A, Conesa J, Marques Vidas M, Prats D, Barrientos Guzmán A.
    Transplant Proc; 2007 Sep; 39(7):2231-2. PubMed ID: 17889147
    [Abstract] [Full Text] [Related]

  • 12. Congenital cytomegalovirus infection as a preventable complication of maternal transfusion. A case report.
    McGregor JA, Rubright G, Ogle JW.
    J Reprod Med; 1990 Jan; 35(1):61-4. PubMed ID: 2153814
    [Abstract] [Full Text] [Related]

  • 13. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
    Roback JD, Conlan M, Drew WL, Ljungman P, Nichols WG, Preiksaitis JK.
    Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
    [Abstract] [Full Text] [Related]

  • 14. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction.
    Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R.
    Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585
    [Abstract] [Full Text] [Related]

  • 15. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB, Lichtiger B.
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prophylaxis and treatment of infection in the bone marrow transplant recipient.
    Winston DJ.
    Curr Clin Top Infect Dis; 1993 Jul; 13():293-321. PubMed ID: 8397916
    [Abstract] [Full Text] [Related]

  • 19. Transfusion-transmitted cytomegalovirus infections: significance and control.
    Tegtmeier GE.
    Vox Sang; 1986 Jul; 51 Suppl 1():22-30. PubMed ID: 3017003
    [Abstract] [Full Text] [Related]

  • 20. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates.
    Brady MT, Milam JD, Anderson DC, Hawkins EP, Speer ME, Seavy D, Bijou H, Yow MD.
    J Infect Dis; 1984 Sep; 150(3):334-9. PubMed ID: 6090541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.